MG-ETP: Education Program in Myasthenia

Sponsor
University Hospital, Strasbourg, France (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04714658
Collaborator
(none)
100
2
51.9

Study Details

Study Description

Brief Summary

Patient therapeutic education (PTE) has become "a must" in the modern management of chronic diseases. Its main objective is to improve compliance with treatment and the application of preventive measures. The main goal of this study is to assess the influence of the therapeutic education program on the perception of the disease in patients with autoimmune myasthenia. Secondary objectives are to assess quality of life, patient satisfaction of the PTE program, the acquisition of therapeutic goals and the influence of therapeutic education on the evolution of autoimmune myasthenia Study team hypothesize that therapeutic education could improve the patient's perception of myasthenia and its quality of life. By improving patient's adherence to treatments and his knowledge of the disease, it could also improve the evolution of myasthenia gravis. Study team suppose that PTE program can reduce the absenteeism at work, the number and duration of hospitalizations, particularly those in intensive care units.

Condition or Disease Intervention/Treatment Phase
  • Other: Therapeutic Education
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Efficiency of a Therapeutic Patient Education Program in Myasthenia Gravis
Anticipated Study Start Date :
Jan 22, 2021
Anticipated Primary Completion Date :
May 22, 2025
Anticipated Study Completion Date :
May 22, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Immediate PTE

Other: Therapeutic Education
Each patient will participate in 1 to 3 PTE sessions. st group collective workshop : allow the patient to better understand autoimmune nd workshop : fatigue and techniques that enable its best management. rd workshop : improving the management of the emotions generated by myasthenia. It allows patients to express their experiences of the disease in front of a group, to talk about their difficulties in their relationships and mobilize their resources to promote exchanges.

Other: 6-month deferred PTE

Other: Therapeutic Education
Each patient will participate in 1 to 3 PTE sessions. st group collective workshop : allow the patient to better understand autoimmune nd workshop : fatigue and techniques that enable its best management. rd workshop : improving the management of the emotions generated by myasthenia. It allows patients to express their experiences of the disease in front of a group, to talk about their difficulties in their relationships and mobilize their resources to promote exchanges.

Outcome Measures

Primary Outcome Measures

  1. Brief Illness Perception Questionnaire [6 month after the first visit]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient with generalized autoimmune myasthenia with Acetylcholine Receptor Antibodies (AChR Ab) or with antibodies to the muscle-specific receptor tyrosine kinase (MuSK Ab)

  • Patient agreeing to participate in the therapeutic education program

  • Signing consent

  • Subject affiliated with a health insurance social protection regiment

Exclusion Criteria:
  • Patients without serological confirmation of myasthenia or pure ocular form

  • Patient with cognitive impairment or behavioral problems that, in the investigator's opinion, will compromise their ability to comply with study procedures

  • Refusal of the patient to participate in the study

  • Patient who has already benefited from the therapeutic education program in myasthenia

  • Age < 18 y.o.

  • Subject under safeguarding justice

  • Subject under guardianship or under curatorship

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University Hospital, Strasbourg, France

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier:
NCT04714658
Other Study ID Numbers:
  • 7534
First Posted:
Jan 19, 2021
Last Update Posted:
Jan 19, 2021
Last Verified:
Nov 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 19, 2021